Lysine specific demethylase 1 inhibitors - Pipeline Insight, 2024

This “Lysine Specific Demethylase 1 (LSD-1) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 11+ companies and 11+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Understanding

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Overview

Lysine-specific demethylase 1 (LSD1) was the first histone demethylase discovered and conserved from fission yeast (S. pombe) to mammals. LSD1 played a pivotal role in a variety of biological processes like cell proliferation, adipogenesis, spermatogenesis, chromosome segregation, pluripotency regulation of stem cell and embryonic development. The discovery of LSD1 in 2004 demonstrated for the first time that histone methylation is a reversible reaction. LSD1 has three structural domains that regulate its enzymatic activity and binding to several proteins. Upon specific stimulation, LSD1 can also act as a transcriptional co-activator. LSD1 is structurally similar to the Flavin-dependent monoamine oxidases (MAOs). Both LSD1 and MAOs utilize flavin adenine dinucleotide (FAD) as cofactor, thus, a number of known MAO inhibitors have been shown to also inhibit LSD1 through irreversible interaction of FAD. The overexpression of LSD1 is reported to be associated with different malignancies. Therefore, the inhibition of LSD1 provides a promising pharmacological target to investigate novel treatments for cancer and other disorders that associate with LSD1’s activity.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Lysine Specific Demethylase 1 (LSD-1) Inhibitor R&D. The therapies under development are focused on novel approaches for Lysine Specific Demethylase 1 (LSD-1) Inhibitor.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs Chapters

This segment of the Lysine Specific Demethylase 1 (LSD-1) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Emerging Drugs

ORY-2001: Oryzon Genomics ORY-1001 is an oral, brain-permeable small molecule. It is a dual inhibitor of the transcriptional co-regulator lysine-specific demethylase 1 (LSD1 or KDM1A) and the mitochondrial membrane protein monoamine oxidase B. The drug is in Phase II clinical studies for the treatment of Aggression, Alzheimer's disease, Borderline personality disorders, Multiple sclerosis, and SARS-CoV-2 acute respiratorydisease.

Domatinostat: 4SCDomatinostat is an orally administered small molecule for the treatment of cancer. The compound inhibits the enzymes histone deacetylase (HDAC) 1, 2, and 3, which are believed to play important roles in the regulation of aberrant cancer signaling. The drug is in Phase II clinical studies for the treatment of Gastrointestinal cancer; Merkel cell carcinoma and in Phase I/II clinical development for Malignant melanoma treatment.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Lysine Specific Demethylase 1 (LSD-1) Inhibitor

There are approx. 11+ key companies which are developing the Lysine Specific Demethylase 1 (LSD-1) Inhibitor. The companies which have their Lysine Specific Demethylase 1 (LSD-1) Inhibitor drug candidates in the most advanced stage, i.e. Phase II include, Oryzon Genomics.

Phases

This report covers around 11+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Lysine Specific Demethylase 1 (LSD-1) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs.

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Insights

• Lysine Specific Demethylase 1 (LSD-1) Inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Lysine Specific Demethylase 1 (LSD-1) Inhibitor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs?
• How many Lysine Specific Demethylase 1 (LSD-1) Inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Lysine Specific Demethylase 1 (LSD-1) Inhibitor?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lysine Specific Demethylase 1 (LSD-1) Inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lysine Specific Demethylase 1 (LSD-1) Inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oryzon Genomics
• 4SC
• Salarius Pharmaceuticals
• Celgene Corporation
• Taiho Pharmaceutical
• CSPC ZhongQi Pharmaceutical Technology
• Beatica
• Rasna Therapeutics

Key Products

• ORY-2001
• Domatinostat
• ORY-3001
• Seclidemstat
• CC-90011
• TAS-1440
• SYHA-1807

Research programme: small molecule therapeutics- RASP-201